From Gleevec To Tasigna: Novartis' Switch Push Kicks Off With Front-Line CML Submission
This article was originally published in The Pink Sheet Daily
Executive Summary
With its blockbuster drug Gleevec headed toward loss of exclusivity in 2015, Novartis is beginning a five-year push to switch patients to Tasigna based on positive data in first-line chronic myeloid leukemia.